Good afternoon, and welcome to the Trevi Therapeutics fourth-quarter and year-end 2024 earnings conference call. (Operator Instructions) Please note, this event is being recorded. Various remarks that ...

The people swiping their cards to pay for food and gas are also paying for wealthy cardholders’ upgrades to business class.

EXEL discovers, develops, and commercializes new treatments to battle hard-to-treat cancers. Its product portfolio continues ...

A collaborative research team from The University of Hong Kong (HKU) and West China Hospital of Sichuan University has made a breakthrough in understanding the spread of oral squamous cell carcinoma ...

CKD and ESRD can have unpleasant cutaneous manifestations, including alopecia, but there are several helpful approaches to mitigating hair loss.

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...

Polycystic kidney disease (PKD), a family of genetic disorders that causes clusters of cysts to form on the kidney, is among the most common genetic disorders, affecting some 500,000 people in the ...

The Religion Communicators Council (RCC) proudly announces the 2025 Wilbur Award recipients, recognizing exceptional work by 20 media outlets completed in 2024 by the secular (non-religious) media in ...

SESAUA annual meeting featured a kidney cancer session and a presentation by Dr. Robert Smith discussing how age and tumor ...

South Texas Health System is honoring World Kidney Day by informing the community on the function of the bean shaped organs ...

Momentum Builds Across Programs with Key Data Milestones Expected in 2025Cemacabtagene Ansegedleucel (Cema-Cel): First-Line (1L) Consolidation in ...

Exelixis' future depends on trial outcomes and patent risks. Find out why EXEL stock is a "Sell" despite cabozantinib's ...